Abstract Exportin 1 (XPO1), also known as chromosome region maintenance protein 1,
plays a crucial role in maintaining cellular homeostasis via the regulated export of a range of …

Chimeric antigen receptor T cells (CAR-T cells) have emerged as a potentially
transformative new approach to treating hematological malignancies. Ide-cel, an autologous …

Introduction: Despite unprecedented advances in the treatment of multiple myeloma (MM),
almost all patients develop a disease that is resistant to the five most commonly used and …

Despite the introduction of immunomodulatory drugs (IMiDs), proteasome inhibitors (PIs),
and, more recently, monoclonal antibodies (mAbs), in the chemotherapy regimens for newly …

Multiple myeloma (MM) represents an incurable hematologic malignancy. Despite
significant advances over the past decade, with the advent of multiple new classes of anti …

Multiple myeloma (MM) is a malignant plasma cell disorder that remains incurable for most
patients, as persistent clonal evolution drives new mutations which confer MM high-risk …

We assessed the safety, efficacy, maximum tolerated dose (MTD), and the recommended
phase 2 dose (RP2D) of selinexor, a first in class oral selective inhibitor of nuclear export …

Mitochondria-targeting damage has become a popular therapeutic option for tumor
metastasis; however, its efficacy is limited by the adaptive rescue capacity of nuclei. There is …

Abstract Exportin 1 (XPO1), also known as chromosome maintenance 1 protein (CRM1), is
the main transporter for hundreds of proteins like tumor suppressors, growth regulatory …

Multiple myeloma (MM) is an incurable malignancy of plasma cells with a clinical course
characterized by multiple relapses and treatment refractoriness. While recent treatment …